121 related articles for article (PubMed ID: 10684157)
1. The role of plasminogen activator receptor in cancer invasion and dormancy.
Ossowski L; Aguirre Ghiso J; Liu D; Yu W; Kovalski K
Medicina (B Aires); 1999; 59(5 Pt 2):547-52. PubMed ID: 10684157
[TBL] [Abstract][Full Text] [Related]
2. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Plesner T; Behrendt N; Ploug M
Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
[TBL] [Abstract][Full Text] [Related]
4. Localization and significance of urokinase plasminogen activator and its receptor in placental tissue from intrauterine, ectopic and molar pregnancies.
Floridon C; Nielsen O; Holund B; Sunde L; Westergaard JG; Thomsen SG; Teisner B
Placenta; 1999 Nov; 20(8):711-21. PubMed ID: 10527826
[TBL] [Abstract][Full Text] [Related]
5. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
[TBL] [Abstract][Full Text] [Related]
6. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK).
Aguirre-Ghiso JA; Estrada Y; Liu D; Ossowski L
Cancer Res; 2003 Apr; 63(7):1684-95. PubMed ID: 12670923
[TBL] [Abstract][Full Text] [Related]
7. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS
Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751
[TBL] [Abstract][Full Text] [Related]
8. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis.
Choong PF; Nadesapillai AP
Clin Orthop Relat Res; 2003 Oct; (415 Suppl):S46-58. PubMed ID: 14600592
[TBL] [Abstract][Full Text] [Related]
9. Heregulin regulation of urokinase plasminogen activator and its receptor: human breast epithelial cell invasion.
Mazumdar A; Adam L; Boyd D; Kumar R
Cancer Res; 2001 Jan; 61(1):400-5. PubMed ID: 11196194
[TBL] [Abstract][Full Text] [Related]
10. Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis.
He Y; Liu XD; Chen ZY; Zhu J; Xiong Y; Li K; Dong JH; Li X
Clin Cancer Res; 2007 Jun; 13(11):3115-24. PubMed ID: 17545513
[TBL] [Abstract][Full Text] [Related]
11. Structural analysis of the interaction between urokinase-type plasminogen activator and its receptor: a potential target for anti-invasive cancer therapy.
Ploug M; Gårdsvoll H; Jørgensen TJ; Lønborg Hansen L; Danø K
Biochem Soc Trans; 2002 Apr; 30(2):177-83. PubMed ID: 12023847
[TBL] [Abstract][Full Text] [Related]
12. DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.
Mamoune A; Kassis J; Kharait S; Kloeker S; Manos E; Jones DA; Wells A
Exp Cell Res; 2004 Sep; 299(1):91-100. PubMed ID: 15302576
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of invasion and metastasis in oral cancer by targeting urokinase-type plasminogen activator receptor.
Nozaki S; Endo Y; Nakahara H; Yoshizawa K; Hashiba Y; Kawashiri S; Tanaka A; Nakagawa K; Matsuoka Y; Kogo M; Yamamoto E
Oral Oncol; 2005 Nov; 41(10):971-7. PubMed ID: 16129656
[TBL] [Abstract][Full Text] [Related]
14. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.
Shariat SF; Roehrborn CG; McConnell JD; Park S; Alam N; Wheeler TM; Slawin KM
J Clin Oncol; 2007 Feb; 25(4):349-55. PubMed ID: 17264329
[TBL] [Abstract][Full Text] [Related]
15. Proteomic identification of lynchpin urokinase plasminogen activator receptor protein interactions associated with epithelial cancer malignancy.
Saldanha RG; Molloy MP; Bdeir K; Cines DB; Song X; Uitto PM; Weinreb PH; Violette SM; Baker MS
J Proteome Res; 2007 Mar; 6(3):1016-28. PubMed ID: 17330942
[TBL] [Abstract][Full Text] [Related]
16. Evolving role of uPA/uPAR system in human cancers.
Dass K; Ahmad A; Azmi AS; Sarkar SH; Sarkar FH
Cancer Treat Rev; 2008 Apr; 34(2):122-36. PubMed ID: 18162327
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
Stillfried GE; Saunders DN; Ranson M
Breast Cancer Res; 2007; 9(1):R14. PubMed ID: 17257442
[TBL] [Abstract][Full Text] [Related]
18. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
19. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
Vines DJ; Lee SW; Dichek DA; Ellis V
J Pept Sci; 2000 Sep; 6(9):432-9. PubMed ID: 11016879
[TBL] [Abstract][Full Text] [Related]
20. Aspirin inhibits highly invasive prostate cancer cells.
Lloyd FP; Slivova V; Valachovicova T; Sliva D
Int J Oncol; 2003 Nov; 23(5):1277-83. PubMed ID: 14532966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
